Voting Rights and Shares Capital of the Company
Nanobiotix (NASDAQ: NBTX) has reported its latest voting rights and share capital status as of July 31, 2025. The company disclosed a total of 48,236,671 shares outstanding, with 50,340,736 theoretical voting rights and 50,318,618 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, with dual listings on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix (NASDAQ: NBTX) ha comunicato lo stato aggiornato dei diritti di voto e del capitale sociale al 31 luglio 2025. La società ha dichiarato un totale di 48.236.671 azioni in circolazione, con 50.340.736 diritti di voto teorici e 50.318.618 diritti di voto esercitabili.
Nanobiotix è un'azienda biotecnologica in fase clinica avanzata con sede a Parigi, quotata su Euronext Paris e sul Nasdaq Global Select Market. Si concentra su approcci terapeutici basati sulla fisica e detiene oltre 25 famiglie di brevetti distribuite su tre piattaforme nanotecnologiche orientate all'oncologia, alla biodisponibilità e biodistribuzione e ai disturbi del sistema nervoso centrale.
Nanobiotix (NASDAQ: NBTX) ha informado su su situación de derechos de voto y capital social a 31 de julio de 2025. La compañía declaró un total de 48.236.671 acciones en circulación, con 50.340.736 derechos de voto teóricos y 50.318.618 derechos de voto ejercitables.
Nanobiotix es una biotecnológica en fase clínica avanzada con sede en París, cotizada en Euronext Paris y en el Nasdaq Global Select Market. Se especializa en enfoques terapéuticos basados en la física y posee más de 25 familias de patentes en tres plataformas nanotecnológicas centradas en oncología, biodisponibilidad y biodistribución, y trastornos del sistema nervioso central.
Nanobiotix (NASDAQ: NBTX)는 2025년 7월 31일 기준 의결권 및 자본 현황을 공시했습니다. 회사는 총 48,236,671주의 발행주식과 50,340,736개의 이론적 의결권, 50,318,618개의 행사 가능한 의결권을 보고했습니다.
Nanobiotix는 파리에 본사를 둔 후기 임상 단계의 바이오테크 기업으로 Euronext Paris와 Nasdaq Global Select Market에 이중 상장되어 있습니다. 물리학 기반의 치료법을 전문으로 하며, 종양학, 생체이용률 및 분포, 중추신경계 질환에 초점을 둔 세 가지 나노기술 플랫폼에 걸쳐 25개 이상의 특허 패밀리를 보유하고 있습니다.
Nanobiotix (NASDAQ: NBTX) a publié la situation de ses droits de vote et de son capital social au 31 juillet 2025. La société a indiqué un total de 48 236 671 actions en circulation, avec 50 340 736 droits de vote théoriques et 50 318 618 droits de vote exerçables.
Nanobiotix est une entreprise biotechnologique en phase clinique avancée, basée à Paris et cotée sur Euronext Paris ainsi que sur le Nasdaq Global Select Market. Elle est spécialisée dans des approches thérapeutiques fondées sur la physique et détient plus de 25 familles de brevets réparties sur trois plateformes nanotechnologiques axées sur l'oncologie, la biodisponibilité et la biodistribution, ainsi que les troubles du système nerveux central.
Nanobiotix (NASDAQ: NBTX) hat seinen aktuellen Stand zu Stimmrechten und Grundkapital zum 31. Juli 2025 veröffentlicht. Das Unternehmen berichtete über insgesamt 48.236.671 ausstehende Aktien sowie 50.340.736 theoretische Stimmrechte und 50.318.618 ausübbare Stimmrechte.
Nanobiotix ist ein klinisch fortgeschrittenes Biotechnologieunternehmen mit Sitz in Paris und Doppelnotierung an der Euronext Paris und dem Nasdaq Global Select Market. Es spezialisiert sich auf physikbasierte Therapieansätze und besitzt über 25 Patentfamilien in drei Nanotechnologie-Plattformen mit Schwerpunkt auf Onkologie, Bioverfügbarkeit und Biodistribution sowie Erkrankungen des zentralen Nervensystems.
- None.
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Aug. 27, 2025 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| July 31, 2025 | 48,236,671 | 50,340,736 | 50,318,618 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachment
- 2025-08-27 -- NBTX -- Voting Rights & Shares Capital -- FINAL
FAQ
What is the current number of outstanding shares for Nanobiotix (NBTX) as of July 2025?
How many voting rights does Nanobiotix (NBTX) have as of July 2025?
What are the main technology platforms of Nanobiotix (NBTX)?
Where is Nanobiotix (NBTX) listed and headquartered?
